ArticleFrontiers in immunology2026
Lymphocyte subsets in untreated thalassemia patients: differences by genotype and age.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Lymphocyte subsets in treatment-naïve patients and their variations among different genetic subtypes and age groups remain poorly characterized. Methods: To characterize the distribution of lymphocyte subsets in treatment-naïve thalassemia patients, stratified by both genetic subtype and age group (pediatric vs. adult), compared to healthy controls. This investigation included 535 participants, comprising 307 healthy controls (104 pediatric and 203 adult patients) and 228 untreated thalassemia patients (123 α-thalassemia, 83 β-thalassemia, and 22 compound α+β-thalassemia cases). Genotyping was performed using NGS, while flow cytometry was utilized to quantify peripheral blood lymphocyte subsets. Results: Pediatric patients: All thalassemia subtypes (α, β, α+β) showed significantly higher Tregs frequencies than healthy pediatric controls (all P < 0.0001). Pediatric α+β-thalassemia patients had lower CD3+ T-cell proportions than β-thalassemia patients.Adult patients: Adult β+-thalassemia patients had significantly higher B-cell and Tregs frequencies than healthy adult controls (P = 0.037, P = 0.034). Adult α+β-thalassemia patients had lower CD4+ T-cell percentages than healthy adult controls (P = 0.040).Age-group comparisons: Tregs levels were significantly higher in healthy adults than in healthy pediatric individuals (P < 0.0001). Pediatric β+-thalassemia patients had lower CD3+ T-cell frequencies than adult β+-thalassemia patients (P = 0.009). Pediatric patients with Hb Constant Spring heterozygosity or Codons 41/42 (-TTCT) β0 heterozygosity also had lower CD3+ and CD4+ T-cell proportions than corresponding adult patients (all P < 0.05). Conclusions: This study clarified the distribution of lymphocyte subsets in treatment-naïve patients with thalassemia. It was found that the number of Tregs in healthy pediatric was significantly lower than that in healthy adults. Moreover, the level of Tregs was markedly higher in pediatric with thalassemia than in healthy pediatric. These findings may help deepen the understanding of immune dysregulation in thalassemia patients and facilitate the formulation of clinical management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.